ESR1 and breast cancer: Among molecules known to behave as ER signaling inhibitors, the change in ER dynamics correlated closely with the ability of these compounds to block estrogen-induced proliferation of estrogen-dependent breast cancer cells, demonstrating the ability of htSMT to document SARs in a chemical series across disparate and biologically relevant readouts.